The chief financial officer of Silence Therapeutics PLC (LON:SLN), David Ellam, has left the gene editing specialist with immediate effect.
Silence’s group head of financial planning and analysis, Rob Quinn, will take on Ellam’s responsibilities for the time being whilst a permanent successor is found.
“On behalf of the board I would like to thank David for his contribution to Silence,” said chief executive David Horn Solomon.
“He has played an important role in building the business and placing Silence Therapeutics in a strong position to continue the development of its product pipeline in the RNAi medicines space. We wish David every success for the future.”